FDA approves GSK- XenoPort postherpetic neuralgia therapy
A single 12-week principal efficacy trial and two supportive studies that met their respective primary endpoints evaluated the efficacy and safety of Horizant. A dosage of 600mg twice
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.